Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst Salveen Richter maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $11 to $13.
Goldman Sachs analyst Salveen Richter maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $11 to $13.